Logo Home   About us   Clinical trial   R&D   Diagnostics   Investors   News   In press   Contact us
Clinical trial

Phase III COLLECT study – patient recruitment is completed

A placebo-controlled, double-blind, randomized, study to assess the efficacy and safety of Kappaproct® as an add-on to current practice in chronic active treatment refractory UC patients.

Study size
120 subjects randomized.

Czech Republic, France, Germany, Hungary, Italy, Poland and UK.

Dosing regime
Two doses of 30 mg 4 weeks apart.

Primary Objective
Clinical remission at week 12.

Secondary Objectives
Time to / rate of colectomy and safety / tolerability during 12 months

For additional details about the study, please visit clinicaltrials.gov.

InDex Pharmaceuticals AB, Tomtebodavägen 23a, 171 77 Stockholm, Phone: +46 8 508 847 30, Fax: +46 8 508 847 39, info@indexpharma.com
Copyright © 2012 InDex Pharmaceuticals AB. All Rights Reserved.